Table 4.
Associations of PTEN Status with Clinical Outcomes after Trastuzumab-Based Therapy in Different Therapeutic Subgroups
| Therapeutic Subgroups | Response |
Overall Survival P Value (Log Rank) | ||
|---|---|---|---|---|
| CR +PR +SD | PD | P Value (Fisher Exact) | ||
| Ttzm as first-line therapy | ||||
| PTEN loss | 24 | 22 | 0.028 | 0.008 |
| PTEN normal | 31 | 10 | ||
| Ttzm as other-line therapy | ||||
| PTEN loss | 13 | 12 | 1.000 | 0.863 |
| PTEN normal | 14 | 11 | ||
| Without prior chemotherapy | ||||
| PTEN loss | 21 | 22 | 0.030 | 0.013 |
| PTEN normal | 35 | 13 | ||
| With prior chemotherapy | ||||
| PTEN loss | 12 | 11 | 1.000 | 0.922 |
| PTEN normal | 9 | 7 | ||
Ttzm indicates trastuzumab; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.